Výsledky vyhledávání - Dominik Heinzmann
- Zobrazuji výsledky 1 - 5 z 5
-
1
Immunogenicity of Trastuzumab Intravenous and Subcutaneous Formulations in the Phase III Hannah Study Autor Roberto Hegg, Tadeusz Pieńkowski, S. Chen, Elżbieta Starosławska, S. Falcon, Н. В. Коваленко, N. Al-Sakaff, Dominik Heinzmann, Gerry Kolaitis, Gustavo Ismael
Vydáno 2012Artigo -
2
Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive... Autor Angelica Quartino, Carina Hillenbach, Jing Li, Hanbin Li, Russell Wada, Jennifer Visich, Chunze Li, Dominik Heinzmann, Jin Y. Jin, Bert L. Lum
Vydáno 2015Artigo -
3
Additional Safety Results of Hannah: A Phase III Randomised, Open-Label, International Study of the Subcutaneous Formulation of Trastuzumab (H) in HER2-Positive Early Breast Cancer... Autor Christian Jackisch, Magdolna Dank, G. Frasci, K.H. Park, R.I. Lopez, Marilyn F.M. Johnston, Dominik Heinzmann, H. Wéber, Gustavo Ismael
Vydáno 2012Artigo -
4
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Autor Christian Jackisch, Daniil Stroyakovskiy, Xavier Pivot, Jin Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Christoph Meyenberg, N. Al-Sakaff, Dominik Heinzmann, Roberto Hegg
Vydáno 2019Artigo -
5
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuva... Autor Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, G. Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot
Vydáno 2016Artigo
Vyhledávací nástroje:
Související témata
Breast cancer
Cancer
Internal medicine
Medicine
Trastuzumab
Oncology
Clinical trial
Confidence interval
Docetaxel
Environmental health
Epirubicin
Hazard ratio
Population
Surgery
Adverse effect
Antibody
Bioavailability
Chemotherapy
Clinical endpoint
Dosing
Gynecology
Immunogenicity
Immunology
NONMEM
Neoadjuvant therapy
Open label
Pharmacokinetics
Pharmacology
Proportional hazards model
Regimen